ADDITIONAL TREATMENT FOR pT3 PROSTATE CANCER: NOW, LATER OR NEVER
Article first published online: 4 JUN 2008
© 2008 THE AUTHORS. JOURNAL COMPILATION © 2008 BJU INTERNATIONAL
Volume 102, Issue 1, page 133, July 2008
How to Cite
Pitts, W. R. (2008), ADDITIONAL TREATMENT FOR pT3 PROSTATE CANCER: NOW, LATER OR NEVER. BJU International, 102: 133. doi: 10.1111/j.1464-410X.2008.07787_1.x
- Issue published online: 4 JUN 2008
- Article first published online: 4 JUN 2008
I read this article  with interest. The Veterans Administration Cooperative Urology Research Group (VACURG) reports of 1968 (I), 1978 (II), 1986 (III) concluded that: (i) diethylstilbestrol (DES) 1 mg/day was safe and effective; (ii) DES 1 mg was more effective than orchidectomy; and (iii) DES 1 mg plus orchidectomy was no better than DES 1 mg alone, as measured by bone scan, acid phosphatase and death. In all of these studies (>40 000 men over 30 years) hormone therapy was initiated immediately on diagnosis .
Scherr et al.[3,4] showed that DES 1 mg prevents the osteoporosis of androgen deprivation. Scherr and Pitts  reviewed the nonsteroidal effects of DES, e.g. those against osteoporosis, angiogenesis, mitosis, tubulin, decrease in cognitive function, atherosclerosis, hot flashes and asthenia. Pitts  reviewed previous reports and showed that immediate androgen deprivation without oestrogen deprivation using DES 1 mg was the only form of therapy to slow progression and prolong life of any prostate cancer therapy (surgery, radiation, orchidectomy or other chemotherapy).
- 2Hormone therapy for prostate cancer: results of the Veterans Administration Co-operative Urology Research Group. NCI Mongr 1988; 7: 165–170, .